Critical issues in gene therapy commercialization: Gene therapy faces the task of building an infrastructure that can connect with the mainstream

Nature Biotechnology

Volumn 15, Issue 7, 1997, Pages 689-690

  Persidis, Aris ^a   Tomczyk, Michael S ^b  

^a Upstate Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOTECHNOLOGY; COST BENEFIT ANALYSIS; ECONOMICS; GENE THERAPY; HUMAN; INDUSTRY; MANPOWER; PUBLIC OPINION;

BIOTECHNOLOGY; COST-BENEFIT ANALYSIS; GENE THERAPY; HUMANS; INDUSTRY; PUBLIC OPINION;

EID: 0031180356     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0797-689     Document Type: Letter

References (0)